US Radioligand Therapy Market

The United States Radioligand Therapy Market size was estimated at USD 3.20 billion in 2025 and is projected to reach USD 10.50 billion by 2035, growing at a CAGR of 12.6% from 2026 to 2035. The sector has become a strategic precision-oncology category supported by FDA approvals, expanding treatment-site infrastructure, specialized manufacturing, diagnostic companion pathways, and pharmaceutical investment.

Key Highlights

• Prostate cancer represented the dominant indication, supported by established PSMA-targeted treatment pathways and expanding eligibility for Pluvicto.
• Actinium-225 represents the fastest-developing radionuclide opportunity as developers advance next-generation alpha-emitting therapies.
• Lutetium-177 remains the leading commercial radionuclide because of established manufacturing, clinical validation, treatment-center familiarity, and approved products.
• Earlier-line treatment expansion is a major demand driver, broadening the addressable patient population and increasing utilization across oncology networks.
• Domestic manufacturing is becoming a strategic differentiator as radioligand products require tightly coordinated isotope sourcing, production, quality release, and time-sensitive delivery.
• Procurement is shifting toward integrated manufacturer-to-treatment-center models, supported by specialty radiopharmacy networks and centralized logistics capabilities.

Market Overview

The United States Radioligand Therapy Market market operates within a highly developed oncology and nuclear-medicine ecosystem where pharmaceutical manufacturers, isotope suppliers, radiopharmacies, diagnostic providers, cancer centers, academic institutions, and specialized logistics operators interact across a tightly coordinated value chain. Commercial adoption is concentrated around precision oncology pathways in which molecular imaging identifies target-positive patients before therapeutic administration. This creates an integrated diagnostic-to-treatment procurement model rather than a conventional pharmaceutical distribution structure. Novartis has established a dedicated US manufacturing footprint for its commercial RLT portfolio, while additional developers are building clinical pipelines around PSMA, SSTR, FAP, GRPR, and other targets. 

Procurement behavior is strongly influenced by product availability, radionuclide supply, treatment-site licensing, radiation-safety infrastructure, reimbursement mechanics, physician expertise, and delivery timing. Treatment centers increasingly require multidisciplinary capabilities spanning nuclear medicine, medical oncology, radiation safety, pharmacy, imaging, and patient scheduling. The resulting commercial ecosystem favors suppliers capable of coordinating product production with individualized patient appointments. This operating model gives established manufacturers with vertically integrated supply chains an advantage while creating opportunities for specialty distributors, radiopharmacies, isotope producers, contract manufacturers, and emerging therapeutic developers.

Key Market Drivers & Industry Demand Dynamics

The first major driver is the expansion of FDA-supported treatment eligibility for PSMA-targeted therapy. Pluvicto received an expanded US indication in 2025 for selected metastatic castration-resistant prostate cancer patients before taxane chemotherapy, followed by another expansion in 2026 into metastatic androgen pathway modulation-naïve or sensitive disease in combination with androgen receptor pathway inhibitor therapy. These regulatory developments move RLT beyond a narrowly defined later-line population and place it earlier within the prostate cancer treatment pathway. The commercial impact extends across imaging, patient identification, treatment-center capacity, isotope supply, and oncology referral networks. Earlier treatment positioning also strengthens the strategic value of PSMA PET diagnostics and coordinated theranostic pathways.

A second driver is the maturation of US manufacturing infrastructure. RLT products require specialized production environments, controlled radioactive-material handling, quality release procedures, and time-sensitive transportation. Novartis opened its third US RLT manufacturing site in Carlsbad in 2025 and has additional facilities planned in Florida and Texas, creating a broader coast-to-coast production network. This infrastructure expansion improves geographic coverage and supports more predictable delivery to treatment centers. For procurement teams, domestic capacity reduces dependence on long-distance international supply chains and strengthens continuity planning for individualized doses.

A third driver is the expansion of the radioligand development pipeline into new targets and radionuclides. Commercial experience with lutetium-177 provides a platform for developers investigating actinium-225, terbium-161, and other therapeutic radionuclides. Pipeline activity increasingly targets tumors beyond prostate cancer and neuroendocrine tumors, including broader solid-tumor applications. Eli Lilly’s RLT pipeline, for example, includes programs directed toward GRPR and fibroblast activation protein targets across multiple solid tumors. This diversification increases the addressable opportunity for isotope suppliers, ligand developers, contract manufacturers, imaging providers, and specialized treatment centers.

A fourth driver is the integration of diagnostic imaging with treatment selection. RLT depends on confirmation that tumors express the relevant molecular target, making PET imaging an operational prerequisite for many therapeutic pathways. Telix expanded Illuccix labeling in 2025 for patient selection before pre-taxane RLT, while its imaging portfolio continues to broaden the theranostic ecosystem. The commercial implication is a stronger linkage between diagnostic radiopharmaceutical distribution and therapeutic RLT utilization. Cancer centers therefore increasingly evaluate imaging availability, scheduling, tracer distribution, therapy capacity, and reimbursement as a connected procurement requirement.

Segmentation Analysis

By Product

Product segmentation separates established commercial therapies from emerging radioligand candidates. Pluvicto represents the largest commercial product category because of its established PSMA-targeted positioning in prostate cancer and expanded treatment eligibility. Lutathera maintains an established role in somatostatin receptor-positive neuroendocrine tumors. Other commercial and pipeline radioligands form the fastest-developing category as pharmaceutical companies progress candidates targeting additional tumor biology. Procurement decisions emphasize regulatory status, clinical evidence, isotope availability, treatment protocol, dose scheduling, and manufacturer supply reliability. Hospitals and cancer centers favor products supported by established administration procedures and reimbursement pathways, while emerging therapies compete through differentiated targets, improved therapeutic profiles, and treatment-line expansion.

By Radionuclide

Lutetium-177 remains the largest radionuclide segment because it underpins commercially established therapies and benefits from mature production, handling, and treatment infrastructure. The isotope has also become embedded within clinical protocols, treatment-center workflows, and supplier relationships. Actinium-225 is the fastest-growing radionuclide opportunity because developers are advancing alpha-emitting approaches designed to deliver highly localized cytotoxic radiation. The strategic challenge centers on scalable isotope production, quality control, supply consistency, and manufacturing integration. Radium-223 remains commercially relevant within targeted bone-metastasis therapy, while other radionuclides represent a broader innovation pipeline. Procurement teams increasingly assess isotope security as a core component of therapeutic sourcing rather than treating it as an upstream technical issue.

By Target

PSMA is the largest target category, supported by established prostate cancer applications, PET-based patient selection, and growing treatment-line eligibility. SSTR represents the second established target platform through neuroendocrine tumor treatment, while other molecular targets represent the fastest-growing innovation category. Emerging approaches increasingly evaluate FAP, GRPR, and other tumor-associated targets across multiple solid tumors. Target selection influences both diagnostic requirements and therapeutic procurement. Commercial success therefore depends on developing a complete theranostic pathway rather than only a therapeutic molecule. Companies with complementary imaging assets, treatment products, manufacturing capabilities, and clinical partnerships possess stronger opportunities to establish integrated platforms.

By Indication

Prostate cancer remains the largest indication because of the commercial maturity of PSMA-targeted RLT and the expansion of Pluvicto into earlier treatment settings. Neuroendocrine tumors form another established application, supported by SSTR-targeted treatment. Other solid tumors represent the fastest-growing opportunity as developers test radioligands against new molecular targets. This segment creates a broader commercial ecosystem involving oncology centers, academic research institutions, diagnostic providers, and specialty radiopharmacies. Procurement requirements vary by indication because patient identification, imaging protocols, treatment frequency, clinical monitoring, and specialist expertise differ. The long-term commercial opportunity is tied to successful clinical validation of new targets and regulatory conversion of pipeline assets into reimbursed treatment pathways.

By Treatment Line

Later-line therapy remains the largest treatment-line segment because currently established RLT utilization has historically concentrated on patients with advanced disease. Earlier-line treatment is the fastest-growing segment following regulatory expansion of Pluvicto and continued clinical investigation of RLT before conventional chemotherapy. Earlier positioning increases the eligible population and changes treatment-center capacity requirements because physicians must incorporate RLT into broader care pathways. Procurement teams therefore evaluate not only product availability but also PET imaging throughput, nuclear medicine staffing, radiation-safety capacity, scheduling systems, and payer authorization processes. Earlier-line adoption also increases the strategic importance of physician education and referral networks because RLT becomes integrated with standard oncology treatment sequencing.

By End User

Hospitals represent the largest end-user category because they possess multidisciplinary oncology, nuclear medicine, pharmacy, imaging, radiation-safety, and inpatient or outpatient infrastructure. Comprehensive cancer centers and academic medical centers represent the fastest-growing institutional segment as clinical research, advanced diagnostics, and early access to emerging RLT programs reinforce their role in therapeutic innovation. Specialty oncology clinics are expanding their relevance as infrastructure becomes more standardized and manufacturer support improves. End-user procurement is increasingly based on total treatment capability rather than individual product price. Institutions evaluate licensing, shielding, imaging access, trained personnel, radioactive-material handling, waste management, reimbursement processes, and patient throughput when determining RLT investment priorities.

By Distribution Channel

Direct manufacturer supply represents the largest distribution channel for established commercial RLT because individualized doses, specialized handling, and strict delivery timing favor coordinated manufacturer-to-treatment-center operations. Specialty distributors and radiopharmacy networks represent the fastest-growing channel as the therapeutic footprint expands and treatment centers require localized logistics. Telix’s acquisition of RLS strengthened its US radiopharmacy network and expanded its last-mile distribution capabilities. SEC Distribution competition is therefore shifting toward geographic reach, delivery reliability, regulatory compliance, inventory coordination, and specialized radioactive-material logistics. Providers with integrated production and distribution capabilities gain procurement relevance by reducing handoffs between isotope production, radiolabeling, quality release, and treatment-site delivery.

Strategic Market Snapshot

The United States Radioligand Therapy Market market is transitioning from a specialized precision-oncology category into a scalable therapeutic platform. Commercial leadership remains concentrated around established PSMA and SSTR applications, while the strongest innovation activity is moving toward earlier treatment lines, alpha-emitting radionuclides, and new molecular targets. The competitive environment is shaped less by conventional pharmaceutical distribution and more by the ability to coordinate diagnostics, isotope supply, manufacturing, quality control, logistics, reimbursement, and treatment-center readiness.

The strategic bottleneck is increasingly operational rather than purely scientific. Companies need dependable isotope access, validated manufacturing processes, specialized personnel, treatment-site partnerships, and predictable patient scheduling. Domestic manufacturing investments therefore have strategic value beyond capacity expansion. They improve supply resilience and shorten delivery pathways for patient-specific products. The commercial landscape favors vertically integrated developers while creating partnership opportunities for radiopharmacies, contract manufacturers, imaging companies, logistics providers, and healthcare systems.

Value Chain, Cost Structure & Procurement Intelligence

The United States value chain spans isotope production, ligand and chelator development, radiolabeling, sterile manufacturing, quality control, packaging, radioactive-material transport, diagnostic imaging, treatment administration, and post-treatment monitoring. The time-sensitive nature of RLT makes inventory management fundamentally different from conventional pharmaceuticals because radioactive decay constrains usable product windows. Local manufacturing is therefore becoming strategically important, with Novartis expanding US production across New Jersey, Indiana, California, Florida, and Texas. 

Cost structures are influenced by isotope sourcing, specialized facilities, regulatory compliance, skilled labor, quality testing, shielding, transportation, imaging, and treatment-center infrastructure. Procurement teams increasingly favor suppliers that provide coordinated delivery and patient scheduling rather than isolated product supply. CMS payment structures also influence institutional economics because therapeutic radiopharmaceuticals can be packaged or separately paid under applicable hospital outpatient payment rules. Specialty radiopharmacy networks add value through last-mile distribution and site coverage.

Market Restraints & Regulatory Challenges

The United States Radioligand Therapy Market market faces regulatory and operational constraints associated with radioactive materials, pharmaceutical manufacturing, nuclear medicine, radiation safety, and patient-specific dosing. FDA approval requires rigorous clinical, chemistry, manufacturing, and controls validation, while treatment facilities operate within federal and applicable state radiation-safety requirements. Manufacturing deficiencies can delay commercialization even when clinical data remain supportive. The FDA’s 2026 complete response to ITM-11 illustrates the commercial importance of CMC and third-party facility readiness. 

Supply-chain constraints also remain relevant because therapeutic radionuclides require specialized production and logistics. Treatment centers need appropriately licensed facilities, trained personnel, radiation-protection procedures, imaging capabilities, and controlled waste-management processes. Reimbursement adds another procurement barrier because payment structures influence treatment-center economics and patient access. CMS maintains specific payment rules for therapeutic radiopharmaceuticals under the hospital outpatient system. These requirements increase entry costs and favor suppliers with regulatory, manufacturing, and logistics depth.

Market Opportunities & Outlook (2026–2035)

The United States Radioligand Therapy Market market presents substantial opportunities through earlier-line treatment, new molecular targets, alpha-emitting radionuclides, domestic manufacturing, and integrated theranostic platforms. Expansion into earlier prostate cancer treatment pathways broadens commercial utilization, while clinical programs targeting FAP, GRPR, and other receptors expand the therapeutic addressable base. 

Automation is also becoming commercially relevant in manufacturing, quality control, dose preparation, scheduling, and logistics. Digital platforms can connect diagnostic eligibility, treatment planning, manufacturing instructions, delivery coordination, and patient records. Localization represents another major opportunity as pharmaceutical companies invest in US production capacity. Sustainability initiatives will increasingly address facility energy use, radioactive-material handling, waste management, packaging, and transportation efficiency. Companies that combine therapeutic innovation with manufacturing scale, diagnostic integration, and treatment-site partnerships are positioned to capture greater value across the ecosystem.

Country-Level Strategic Insights

The United States provides the most developed commercial environment for RLT because of its large oncology infrastructure, sophisticated pharmaceutical industry, established nuclear-medicine capabilities, advanced reimbursement systems, and deep biotechnology investment base. The investment climate increasingly supports domestic pharmaceutical manufacturing and advanced therapeutic infrastructure. Novartis has committed to a broad US manufacturing and R&D expansion program that includes dedicated RLT facilities, while additional developers are building US clinical and manufacturing capabilities. 

The industrial ecosystem is centered around pharmaceutical innovators, isotope suppliers, radiopharmacies, academic medical centers, cancer networks, imaging companies, contract manufacturers, and specialized logistics providers. Domestic production is gaining strategic importance because RLT products require coordinated manufacturing and rapid delivery. Novartis’ California, Indiana, and New Jersey facilities already provide a distributed production structure, with Florida and Texas facilities under development. 

Consumer behavior is represented primarily by physician-led treatment selection and patient referral pathways rather than conventional direct pharmaceutical purchasing. Access depends on molecular testing, PET imaging, specialist referral, treatment-site availability, payer authorization, and clinical infrastructure. Distribution is therefore concentrated around healthcare systems and specialized radiopharmacy networks. Innovation is supported by biotechnology clusters, academic research institutions, venture investment, and partnerships between pharmaceutical companies and emerging radiopharmaceutical developers.

Technology, Innovation & Industry Trends

Technology development in the United States Radioligand Therapy Market market is increasingly centered on precision targeting, advanced radionuclide production, automated manufacturing, molecular imaging, and data-supported treatment planning. AI and analytics support patient identification, imaging interpretation, clinical-trial recruitment, dosimetry research, and operational scheduling, while automation improves reproducibility in radiolabeling and dose preparation.

Manufacturing innovation is particularly important because radioactive products require precise coordination between isotope availability, ligand production, radiolabeling, quality release, packaging, and transport. Novartis describes its RLT infrastructure as vertically integrated from isotope production through final delivery, while its Indianapolis expansion is designed to support in-house isotope production. 

The technology pipeline is also moving beyond established lutetium-177 applications. Actinium-225 is receiving substantial development attention because alpha particles provide a differentiated therapeutic mechanism. Digital platforms connecting PET diagnostics, treatment authorization, manufacturing, and logistics are becoming increasingly important as treatment volumes expand. Sustainability efforts will focus on facility efficiency, controlled radioactive waste handling, packaging optimization, and localized supply networks.

Competitive Landscape Overview

The competitive landscape in the United States combines established pharmaceutical companies, radiopharmaceutical specialists, isotope suppliers, biotechnology developers, and contract manufacturing organizations. Novartis maintains the strongest commercial position through approved RLT products and an integrated US manufacturing network. Its strategy emphasizes manufacturing localization, geographic distribution, treatment-site access, and pipeline expansion. 

Bristol Myers Squibb has strengthened its RLT position through RayzeBio, including the RYZ101 program targeting SSTR-positive neuroendocrine tumors. In 2026, the ACTION-1 Phase 3 interim analysis reported a positive progression-free survival result, reinforcing the commercial importance of next-generation alpha-emitting RLT approaches. 

Telix combines diagnostic and therapeutic radiopharmaceutical capabilities with a growing US distribution infrastructure, while ITM brings isotope production and therapeutic development expertise. Eli Lilly is building a broader RLT pipeline around novel targets. Competition therefore centers on clinical differentiation, isotope security, manufacturing scalability, regulatory execution, diagnostic integration, treatment-site relationships, and supply reliability rather than product pricing alone.

Key Players in the US Radioligand Therapy Market

The United States Radioligand Therapy Market market includes established pharmaceutical companies, radiopharmaceutical specialists, isotope manufacturers, biotechnology companies, and developers advancing next-generation targeted therapies. The competitive set reflects both commercial products and meaningful clinical-stage programs operating within the US ecosystem.

• Novartis
• Bristol Myers Squibb
• Eli Lilly and Company
• Telix Pharmaceuticals
• ITM Isotope Technologies Munich
• Bayer
• AstraZeneca
• Ratio Therapeutics
• Perspective Therapeutics
• Fusion Pharmaceuticals
• Y-mAbs Therapeutics
• Clarity Pharmaceuticals

Recent Developments 

Recent developments demonstrate accelerating commercialization, manufacturing localization, diagnostic expansion, and pipeline diversification across the US ecosystem.

• January 2026 — Novartis — Announced a new RLT manufacturing facility in Winter Park, Florida — strengthened planned delivery coverage across the Southeast. 
• February 2026 — Novartis — Announced a new RLT manufacturing site in Denton, Texas — expanded planned capacity for Southern US treatment demand. 
• July 2026 — FDA — Expanded Pluvicto eligibility to an earlier metastatic prostate cancer population — broadened the commercial treatment opportunity. 
• October 2026 — Bristol Myers Squibb — Reported positive Phase 3 ACTION-1 interim results for RYZ101 — reinforced the development case for alpha-emitting RLT in NETs. 
• September 2026 — Telix — Received FDA approval for Pixclara brain-cancer imaging — expanded the US theranostic and precision-imaging ecosystem. 
• November 2025 — Novartis — Opened its Carlsbad, California RLT manufacturing facility — expanded production coverage for Western US patients. 
• June 2025 — Telix — Received FDA label expansion for Illuccix for pre-taxane RLT patient selection — strengthened the diagnostic-to-treatment pathway.

Methodology & Data Credibility

The report uses a bottom-up modeling framework designed to quantify the US radioligand therapy ecosystem through product-level, indication-level, treatment-line, end-user, and distribution analysis. Market estimates are triangulated through company disclosures, regulatory documentation, clinical-development information, healthcare utilization indicators, manufacturing capacity assessments, procurement structures, and expert inputs. Executive interviews support demand-side validation across pharmaceutical, oncology, nuclear-medicine, radiopharmacy, and healthcare-provider stakeholders.

Supply-side validation assesses product availability, manufacturing infrastructure, isotope sourcing, distribution networks, treatment-site expansion, and competitive pipeline activity. Demand-side validation examines patient pathways, physician adoption, diagnostic requirements, treatment capacity, reimbursement conditions, and institutional procurement behavior. Country-level verification incorporates FDA requirements, CMS payment structures, radiation-safety considerations, domestic manufacturing developments, and US supply-chain conditions.

Who Should Read This Report

This report is designed for pharmaceutical executives, radiopharmaceutical developers, biotechnology companies, isotope producers, healthcare investors, oncology strategy teams, nuclear-medicine operators, radiopharmacy networks, contract manufacturers, diagnostic companies, and healthcare procurement leaders. It also supports consulting firms, investment institutions, corporate development teams, and technology providers evaluating opportunities across precision oncology.

The analysis is particularly relevant for organizations assessing RLT commercialization, manufacturing localization, treatment-site expansion, diagnostic integration, isotope procurement, competitive positioning, and strategic partnerships. Investors can use the study to evaluate commercial maturity, pipeline diversification, manufacturing barriers, and value-chain opportunities. Healthcare providers can use it to assess infrastructure requirements and procurement priorities associated with expanding RLT services.

What This Report Delivers

The report delivers a country-specific assessment of the United States radioligand therapy ecosystem covering market size, forecast outlook, competitive structure, product development, therapeutic indications, radionuclide dynamics, molecular targets, treatment lines, end-user demand, and distribution models. It evaluates the commercial implications of FDA approvals, domestic manufacturing investment, diagnostic integration, isotope availability, reimbursement, and treatment-center infrastructure.

The study also provides procurement intelligence covering supply-chain configuration, manufacturing localization, radiopharmacy distribution, treatment-site requirements, and operational constraints. Strategic analysis identifies the segments with the strongest commercial positioning and the areas receiving the greatest development activity. The report is structured to support investment decisions, market-entry strategies, partnership development, commercialization planning, and long-term portfolio prioritization.

Market Report Segmentation

By Product

• Pluvicto
• Lutathera
• Other Commercial and Pipeline Radioligands

By Radionuclide

• Lutetium-177
• Actinium-225
• Radium-223
• Other Radionuclides

By Target

• PSMA
• SSTR
• Other Molecular Targets

By Indication

• Prostate Cancer
• Neuroendocrine Tumors
• Other Solid Tumors

By Treatment Line

• Later-Line
• Earlier-Line
• Maintenance/Consolidation

By End User

• Hospitals
• Comprehensive Cancer Centers
• Academic Medical Centers
• Specialty Oncology Clinics

By Distribution Channel

• Direct Manufacturer Supply
• Specialty Distributors and Radiopharmacy Networks